Shanghai Bao Pharmaceuticals Co., Ltd. (HKG:2659)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
17.97
-0.06 (-0.33%)
Jun 18, 2026, 4:08 PM HKT
Market Cap5.88B
Revenue (ttm)54.70M +698.0%
Net Income-439.90M
EPS-1.52
Shares Out 325.98M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,142,000
Open17.88
Previous Close18.03
Day's Range17.85 - 18.67
52-Week Range17.81 - 206.00
Betan/a
Analystsn/a
Price Targetn/a
Earnings DateMar 26, 2026

About HKG:2659

Shanghai Bao Pharmaceuticals Co., Ltd., a biotechnology company, engages in the research, development, and commercialization of pharmaceutical products in Mainland China. The company uses synthetic biology technology to develop and deliver recombinant biologic drugs. Its products include KJ017, a recombinant human hyaluronidase for subcutaneous drug delivery; KJ103, a recombinant immunoglobulin G (IgG)-degrading enzyme for IgG-mediated autoimmune diseases; and SJ02, a long-acting recombinant human follicle-stimulating hormone carboxyl-terminal ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2019
Employees 354
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2659
Full Company Profile

Financial Performance

In 2025, HKG:2659's revenue was 49.16 million, an increase of 697.99% compared to the previous year's 6.16 million. Losses were -395.30 million, 8.47% more than in 2024.

Financial numbers in CNY Financial Statements